Aldeyra Therapeutics Shares Rise 9.2% on Trial Outcome for Dry Eye Disease Treatment

Dow Jones08-08

By Denny Jacob

Aldeyra Therapeutics shares were up 9.2% in premarket trading after achieving the primary endpoint in a Phase 3 clinical trial of a dry eye disease treatment.

Shares were recently trading around $3.56. The stock is down 7.1% on the year.

The biotechnology company said Reproxalap was statistically superior to vehicle for the prespecified primary endpoint of ocular discomfort, a Food and Drug Administration accepted symptom of dry eye disease.

Aldeyra said the trial was designed to satisfy the FDA's new drug application resubmission requirement, which is expected to take place this year. The review period by the FDA is expected to be six months.

Write to Denny Jacob at denny.jacob@wsj.com

(END) Dow Jones Newswires

August 08, 2024 08:24 ET (12:24 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2457397294?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-08-08 20:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2457397294","market":"hk","top_or_hot":-1,"title":"Aldeyra Therapeutics Shares Rise 9.2% on Trial Outcome for Dry Eye Disease Treatment","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Denny Jacob \n</p>\n<pre>\n \n</pre>\n<p>\n  Aldeyra <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> shares were up 9.2% in premarket trading after achieving the primary endpoint in a Phase 3 clinical trial of a dry eye disease treatment. \n</p>\n<p>\n  Shares were recently trading around $3.56. The stock is down 7.1% on the year. \n</p>\n<p>\n  The biotechnology company said Reproxalap was statistically superior to vehicle for the prespecified primary endpoint of ocular discomfort, a Food and Drug Administration accepted symptom of dry eye disease. \n</p>\n<p>\n  Aldeyra said the trial was designed to satisfy the FDA's new drug application resubmission requirement, which is expected to take place this year. The review period by the FDA is expected to be six months. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Denny Jacob at denny.jacob@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 08, 2024 08:24 ET (12:24 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aldeyra Therapeutics Shares Rise 9.2% on Trial Outcome for Dry Eye Disease Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAldeyra Therapeutics Shares Rise 9.2% on Trial Outcome for Dry Eye Disease Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-08 20:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Denny Jacob \n\n\n \n\n\n  Aldeyra Therapeutics shares were up 9.2% in premarket trading after achieving the primary endpoint in a Phase 3 clinical trial of a dry eye disease treatment. \n\n\n  Shares were ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALDX","symbol_name":"Aldeyra Therapeutics Inc","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2457397294","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2457397294","pubTimestamp":1723119840,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Aldeyra Therapeutics shares were up 9.2% in premarket trading after achieving the primary endpoint in a Phase 3 clinical trial of a dry eye disease treatment.Shares were recently trading around $3.56. The stock is down 7.1% on the year.The biotechnology company said Reproxalap was statistically superior to vehicle for the prespecified primary endpoint of ocular discomfort, a Food and Drug Administration accepted symptom of dry eye disease.Aldeyra said the trial was designed to satisfy the FDA's new drug application resubmission requirement, which is expected to take place this year. The review period by the FDA is expected to be six months.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ALDX":"Aldeyra Therapeutics Inc","BK4139":"生物科技"},"translate_title":"Aldeyra Therapeutics股价因干眼症治疗试验结果上涨9.2%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALDX":1},"content_text":"By Denny Jacob \n\n\n \n\n\n  Aldeyra Therapeutics shares were up 9.2% in premarket trading after achieving the primary endpoint in a Phase 3 clinical trial of a dry eye disease treatment. \n\n\n  Shares were recently trading around $3.56. The stock is down 7.1% on the year. \n\n\n  The biotechnology company said Reproxalap was statistically superior to vehicle for the prespecified primary endpoint of ocular discomfort, a Food and Drug Administration accepted symptom of dry eye disease. \n\n\n  Aldeyra said the trial was designed to satisfy the FDA's new drug application resubmission requirement, which is expected to take place this year. The review period by the FDA is expected to be six months. \n\n\n \n\n\n  Write to Denny Jacob at denny.jacob@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 08, 2024 08:24 ET (12:24 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.2","shortVersion":"4.28.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2457397294"}